[Skip to Content]
[Skip to Content Landing]
October 2000

Skin Bioequivalents and Their Role in the Treatment of Inherited Epidermolysis Bullosa

Author Affiliations

Copyright 2000 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2000

Arch Dermatol. 2000;136(10):1259-1260. doi:10.1001/archderm.136.10.1259

IN THE current issue of the ARCHIVES, Falabella and colleagues1 report on their expanded experience with the use of Apligraf (Organogenesis Inc, Canton, Mass), a commercially available artificial skin bioequivalent, in the treatment of acute and chronic wounds in 15 patients with inherited epidermolysis bullosa (EB). This study is a natural extension of their positive experience in the short-term treatment of an infant with a generalized form of EB simplex.2 This extended report is a timely and highly anticipated one, since the EB lay organizations (Dystrophic EB Research Association) in North America and Europe, the National EB Registry, and other centers involved in EB research and treatment have received hundreds of requests for information on this potential breakthrough in the day-to-day management of this disease.